Overview

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Bayer
Treatments:
Hormones
Mitoxantrone
Molgramostim
Sargramostim